While Boehringer Ingelheim GmbH seeks to convince doctors its new EGFR inhibitor Gilotrif afatinib is preferable to Tarceva erlotinib for first-line non-small cell lung cancer, Qiagen N.V. will be working to drive adoption of its therascreen EGFR RGQ PCR Kit in the face of other alternatives.

Qiagen plans to encourage physician uptake of its test by emphasizing its accuracy and clinical validity over lab-based methods, while working with individual payers to increase reimbursement.